BCG/Immunotherapy Strategies in BCG-Naïve NMIBC

In this interview, Tom Jayram, MD, offers insights into how BCG plus immune checkpoint inhibitors may redefine the treatment landscape in BCG-naïve NMIBC.

Suzanne B. Merrill, MD, FACS explains the challenges with BCG monotherapy and the emergence of novel regimens combining BCG with ICIs in high-risk NMIBC.

Take a look through the key trials investigating BCG/ICI combinations in BCG-naïve NMIBC.

Chad A. Reichard, MD, outlines key findings from the CREST trial, evaluating the combination of sasanlimab plus BCG in patients with high-risk BCG-naïve NMIBC.

According to the authors, immune-mediated adverse events were manageable and consistent with the known profiles for ICIs.

Suzanne B. Merrill, MD, FACS, discussed the feasibility of integrating immune checkpoint inhibitors into clinical practice for NMIBC, particularly in the community setting.